Testosterone and benign prostatic hyperplasia

The use of testosterone to treat the symptoms of late-onset hypogonadal men has increased recently due to patient and physician awareness. However, concerns regarding the effect of testosterone on the prostate, in particular any possible effect on the risk of prostate cancer have prompted further re...

Full description

Bibliographic Details
Main Authors: Jarvis, Thomas R, Chughtai, Bilal, Kaplan, Steven A
Format: Online
Language:English
Published: Medknow Publications & Media Pvt Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650459/
id pubmed-4650459
recordtype oai_dc
spelling pubmed-46504592015-12-10 Testosterone and benign prostatic hyperplasia Jarvis, Thomas R Chughtai, Bilal Kaplan, Steven A Invited Review The use of testosterone to treat the symptoms of late-onset hypogonadal men has increased recently due to patient and physician awareness. However, concerns regarding the effect of testosterone on the prostate, in particular any possible effect on the risk of prostate cancer have prompted further research in this regard. Surprisingly, numerous retrospective or small, randomized trials have pointed to a possible improvement in male lower urinary tract symptoms (LUTS) in patients treated with testosterone. The exact mechanism of this improvement is still debated but may have a close relationship to metabolic syndrome. For the clinician, the results of these studies are promising but do not constitute high levels of evidence. A thorough clinical examination (including history, examination and laboratory testing of testosterone) should be undertaken before considering the diagnosis of late-onset hypogonadism or instigating treatment for it. Warnings still remain on the testosterone supplement product labels regarding the risk of urinary retention and worsening LUTS, and these should be explained to patients. Medknow Publications & Media Pvt Ltd 2015 2014-10-21 /pmc/articles/PMC4650459/ /pubmed/25337845 http://dx.doi.org/10.4103/1008-682X.140966 Text en Copyright: © Asian Journal of Andrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Jarvis, Thomas R
Chughtai, Bilal
Kaplan, Steven A
spellingShingle Jarvis, Thomas R
Chughtai, Bilal
Kaplan, Steven A
Testosterone and benign prostatic hyperplasia
author_facet Jarvis, Thomas R
Chughtai, Bilal
Kaplan, Steven A
author_sort Jarvis, Thomas R
title Testosterone and benign prostatic hyperplasia
title_short Testosterone and benign prostatic hyperplasia
title_full Testosterone and benign prostatic hyperplasia
title_fullStr Testosterone and benign prostatic hyperplasia
title_full_unstemmed Testosterone and benign prostatic hyperplasia
title_sort testosterone and benign prostatic hyperplasia
description The use of testosterone to treat the symptoms of late-onset hypogonadal men has increased recently due to patient and physician awareness. However, concerns regarding the effect of testosterone on the prostate, in particular any possible effect on the risk of prostate cancer have prompted further research in this regard. Surprisingly, numerous retrospective or small, randomized trials have pointed to a possible improvement in male lower urinary tract symptoms (LUTS) in patients treated with testosterone. The exact mechanism of this improvement is still debated but may have a close relationship to metabolic syndrome. For the clinician, the results of these studies are promising but do not constitute high levels of evidence. A thorough clinical examination (including history, examination and laboratory testing of testosterone) should be undertaken before considering the diagnosis of late-onset hypogonadism or instigating treatment for it. Warnings still remain on the testosterone supplement product labels regarding the risk of urinary retention and worsening LUTS, and these should be explained to patients.
publisher Medknow Publications & Media Pvt Ltd
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650459/
_version_ 1613503075573563392